vs
IMAX（IMAX）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是IMAX的1.1倍（$139.1M vs $125.2M），VERACYTE, INC.净利率更高（20.6% vs 0.5%，领先20.1%），IMAX同比增速更快（35.1% vs 21.5%），过去两年IMAX的营收复合增速更高（25.8% vs 10.2%）
IMAX公司是加拿大的影视放映技术企业，1967年创立于蒙特利尔，总部位于多伦多地区，在纽约、洛杉矶均设有业务点。核心业务包括IMAX摄影机与放映系统的设计制造，同时面向全球合作影院提供影片开发、制作、后期及发行服务，是沉浸式观影技术领域的领先企业。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
IMAX vs VCYT — 直观对比
营收规模更大
VCYT
是对方的1.1倍
$125.2M
营收增速更快
IMAX
高出13.6%
21.5%
净利率更高
VCYT
高出20.1%
0.5%
两年增速更快
IMAX
近两年复合增速
10.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $125.2M | $139.1M |
| 净利润 | $637.0K | $28.7M |
| 毛利率 | 57.6% | 72.7% |
| 营业利润率 | 19.3% | 16.3% |
| 净利率 | 0.5% | 20.6% |
| 营收同比 | 35.1% | 21.5% |
| 净利润同比 | -88.0% | — |
| 每股收益（稀释后） | $0.02 | $0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IMAXVCYT
| Q1 26 | — | $139.1M | ||
| Q4 25 | $125.2M | $140.6M | ||
| Q3 25 | $106.7M | $131.9M | ||
| Q2 25 | $91.7M | $130.2M | ||
| Q1 25 | $86.7M | $114.5M | ||
| Q4 24 | $92.7M | $118.6M | ||
| Q3 24 | $91.5M | $115.9M | ||
| Q2 24 | $89.0M | $114.4M |
净利润IMAXVCYT
| Q1 26 | — | $28.7M | ||
| Q4 25 | $637.0K | $41.1M | ||
| Q3 25 | $20.7M | $19.1M | ||
| Q2 25 | $11.3M | $-980.0K | ||
| Q1 25 | $2.3M | $7.0M | ||
| Q4 24 | $5.3M | $5.1M | ||
| Q3 24 | $13.9M | $15.2M | ||
| Q2 24 | $3.6M | $5.7M |
毛利率IMAXVCYT
| Q1 26 | — | 72.7% | ||
| Q4 25 | 57.6% | 72.5% | ||
| Q3 25 | 63.1% | 69.2% | ||
| Q2 25 | 58.5% | 69.0% | ||
| Q1 25 | 61.4% | 69.5% | ||
| Q4 24 | 52.2% | 66.4% | ||
| Q3 24 | 55.8% | 68.2% | ||
| Q2 24 | 49.4% | 68.1% |
营业利润率IMAXVCYT
| Q1 26 | — | 16.3% | ||
| Q4 25 | 19.3% | 26.4% | ||
| Q3 25 | 27.2% | 17.4% | ||
| Q2 25 | 15.6% | -4.0% | ||
| Q1 25 | 19.3% | 2.5% | ||
| Q4 24 | 10.3% | 3.5% | ||
| Q3 24 | 21.2% | 10.4% | ||
| Q2 24 | 3.2% | 4.0% |
净利率IMAXVCYT
| Q1 26 | — | 20.6% | ||
| Q4 25 | 0.5% | 29.3% | ||
| Q3 25 | 19.4% | 14.5% | ||
| Q2 25 | 12.3% | -0.8% | ||
| Q1 25 | 2.7% | 6.2% | ||
| Q4 24 | 5.7% | 4.3% | ||
| Q3 24 | 15.2% | 13.1% | ||
| Q2 24 | 4.0% | 5.0% |
每股收益（稀释后）IMAXVCYT
| Q1 26 | — | $0.35 | ||
| Q4 25 | $0.02 | $0.50 | ||
| Q3 25 | $0.37 | $0.24 | ||
| Q2 25 | $0.20 | $-0.01 | ||
| Q1 25 | $0.04 | $0.09 | ||
| Q4 24 | $0.09 | $0.07 | ||
| Q3 24 | $0.26 | $0.19 | ||
| Q2 24 | $0.07 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $151.2M | $439.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $337.9M | $1.3B |
| 总资产 | $894.0M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IMAXVCYT
| Q1 26 | — | $439.1M | ||
| Q4 25 | $151.2M | $362.6M | ||
| Q3 25 | $143.1M | $315.6M | ||
| Q2 25 | $109.3M | $219.5M | ||
| Q1 25 | $97.1M | $186.1M | ||
| Q4 24 | $100.6M | $239.1M | ||
| Q3 24 | $104.5M | $274.1M | ||
| Q2 24 | $91.6M | $235.9M |
股东权益IMAXVCYT
| Q1 26 | — | $1.3B | ||
| Q4 25 | $337.9M | $1.3B | ||
| Q3 25 | $349.5M | $1.3B | ||
| Q2 25 | $320.4M | $1.2B | ||
| Q1 25 | $299.5M | $1.2B | ||
| Q4 24 | $299.5M | $1.2B | ||
| Q3 24 | $289.4M | $1.2B | ||
| Q2 24 | $267.2M | $1.1B |
总资产IMAXVCYT
| Q1 26 | — | $1.4B | ||
| Q4 25 | $894.0M | $1.4B | ||
| Q3 25 | $889.6M | $1.4B | ||
| Q2 25 | $868.6M | $1.3B | ||
| Q1 25 | $848.3M | $1.3B | ||
| Q4 24 | $830.4M | $1.3B | ||
| Q3 24 | $847.6M | $1.3B | ||
| Q2 24 | $827.4M | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $29.4M | $35.2M |
| 自由现金流经营现金流 - 资本支出 | $28.0M | — |
| 自由现金流率自由现金流/营收 | 22.3% | — |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | 46.11× | 1.23× |
| 过去12个月自由现金流最近4个季度 | $118.9M | — |
8季度趋势，按日历期对齐
经营现金流IMAXVCYT
| Q1 26 | — | $35.2M | ||
| Q4 25 | $29.4M | $52.6M | ||
| Q3 25 | $67.5M | $44.8M | ||
| Q2 25 | $23.2M | $33.6M | ||
| Q1 25 | $7.0M | $5.4M | ||
| Q4 24 | $11.5M | $24.5M | ||
| Q3 24 | $35.3M | $30.0M | ||
| Q2 24 | $35.0M | $29.6M |
自由现金流IMAXVCYT
| Q1 26 | — | — | ||
| Q4 25 | $28.0M | $48.8M | ||
| Q3 25 | $64.8M | $42.0M | ||
| Q2 25 | $20.9M | $32.3M | ||
| Q1 25 | $5.3M | $3.5M | ||
| Q4 24 | $6.9M | $20.4M | ||
| Q3 24 | $34.2M | $27.7M | ||
| Q2 24 | $33.5M | $26.8M |
自由现金流率IMAXVCYT
| Q1 26 | — | — | ||
| Q4 25 | 22.3% | 34.7% | ||
| Q3 25 | 60.7% | 31.8% | ||
| Q2 25 | 22.8% | 24.8% | ||
| Q1 25 | 6.1% | 3.1% | ||
| Q4 24 | 7.4% | 17.2% | ||
| Q3 24 | 37.3% | 23.9% | ||
| Q2 24 | 37.6% | 23.4% |
资本支出强度IMAXVCYT
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | 2.7% | ||
| Q3 25 | 2.6% | 2.1% | ||
| Q2 25 | 2.6% | 1.0% | ||
| Q1 25 | 1.9% | 1.6% | ||
| Q4 24 | 5.0% | 3.5% | ||
| Q3 24 | 1.2% | 1.9% | ||
| Q2 24 | 1.8% | 2.4% |
现金转化率IMAXVCYT
| Q1 26 | — | 1.23× | ||
| Q4 25 | 46.11× | 1.28× | ||
| Q3 25 | 3.27× | 2.34× | ||
| Q2 25 | 2.06× | — | ||
| Q1 25 | 2.99× | 0.76× | ||
| Q4 24 | 2.16× | 4.80× | ||
| Q3 24 | 2.54× | 1.98× | ||
| Q2 24 | 9.78× | 5.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IMAX
| Technology Sales | $46.6M | 37% |
| Image Enhancement And Maintenance Services | $38.1M | 30% |
| Joint Revenue Sharing Arrangement | $20.4M | 16% |
| Maintenance | $16.3M | 13% |
| Finance Income | $2.8M | 2% |
| Other Content Solutions | $1.6M | 1% |
VCYT
| Testing revenue | $135.1M | 97% |
| Product revenue | $3.7M | 3% |
| Biopharmaceutical and other revenue | $301.0K | 0% |
